Contact Us
Drug Search Results
More Filters [+]

Milatuzumab

Alternative Names: milatuzumab, hll1, immu-115
Latest Update: 2023-09-22
Latest Update Note: PubMed Publication

Product Description

Milatuzumab (hLL1), a humanized anti-CD74 monoclonal antibody, has activity in preclinical NHL models.

Mechanisms of Action: CD74 Inhibitor

Novel Mechanism: Yes

Modality: Antibody

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Gilead Sciences
Company Location: FOSTER CITY CA 94404
Company CEO: Daniel P. O’Day
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Milatuzumab

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Lymphoma, Non-Hodgkin|Chronic Lymphoid Leukemia|Lymphoma, B-Cell|Lymphocytic Chronic B-Cell Leukemia|Plasmacytoma|Multiple Myeloma

Phase 1: Follicular Lymphoma|Precursor B-Cell Lymphoblastic Leukemia-Lymphoma|Lymphocytic Chronic B-Cell Leukemia|Graft vs Host Disease|Preleukemia|Acute Myeloid Leukemia|Myelogenous, Chronic, BCR-ABL Positive Leukemia|Chronic Myeloid Leukemia|Myelodysplastic Syndrome|Diffuse Large B-Cell Lymphoma|Acute Lymphoid Leukemia|Leukemia, Plasma Cell|Chronic Lymphoid Leukemia|Multiple Myeloma|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Lupus Erythematosus, Cutaneous|Lymphoma, Non-Hodgkin|Lymphoma, B-Cell|Lupus Nephritis|Lupus Vasculitis|Systemic Vasculitis|Vasculitis, Central Nervous System|Lupus Erythematosus, Discoid|Lupus Erythematosus, Systemic

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
IM-T-hLL1-DOX-02

P2

Terminated

Lymphoma, B-Cell|Lymphocytic Chronic B-Cell Leukemia|Chronic Lymphoid Leukemia|Lymphoma, Non-Hodgkin

2016-11-01

42%
OSU-09024

P2

Completed

Lymphoma, B-Cell|Lymphoma, Non-Hodgkin

2015-04-01

IM-T-IMMU-115-03

P1

Terminated

Myelodysplastic Syndrome|Myelogenous, Chronic, BCR-ABL Positive Leukemia|Diffuse Large B-Cell Lymphoma|Acute Myeloid Leukemia|Chronic Myeloid Leukemia|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Leukemia, Plasma Cell|Follicular Lymphoma|Precursor B-Cell Lymphoblastic Leukemia-Lymphoma|Graft vs Host Disease|Multiple Myeloma|Chronic Lymphoid Leukemia|Acute Lymphoid Leukemia|Preleukemia|Lymphocytic Chronic B-Cell Leukemia

2015-03-01

42%
IM-T-hLL1-DOX-01

P2

Terminated

Multiple Myeloma

2013-07-01

Recent News Events

Date

Type

Title

09/22/2023

PubMed

 A novel CAR-T cell product targeting CD74 is an effective therapeutic approach in preclinical mantle cell lymphoma models.

12/15/2022

PubMed

 The first ADC bearing the ferroptosis inducer RSL3 as a payload with conservation of the fragile electrophilic warhead.

07/01/2021

PubMed

 Experience with milatuzumab, an anti-CD74 antibody against immunomodulatory macrophage migration inhibitory factor (MIF) receptor, for systemic lupus erythematosus (SLE).

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions